$IDXG

INTERPACE BIOSCIENCES, INC.

CIK:0001054102|SEC Filings

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Revenue, net	$ 9,131	$ 9,232	$ 18,163	$ 20,747
Cost of revenue	3,478	3,956	6,606	8,101
Gross profit	5,653	5,276	11,557	12,646
Operating expenses:
Sales and marketing	2,207	2,910	4,384	5,723
Research and development	149	173	301	350
General and administrative	2,976	2,661	5,427	5,211
Total operating expenses	5,332	5,744	10,112	11,284
Operating income (loss) from continuing operations	321	(468)	1,445	1,362
Note payable interest		(49)		(127)
Other income (expense), net	9	(16)	18	4
Income (loss) from continuing operations before tax	330	(533)	1,463	1,239
Provision for income taxes	64		366	18
Income (loss) from continuing operations	266	(533)	1,097	1,221
Loss from discontinued operations, net of tax	(108)	(107)	(218)	(214)
Net income (loss)	$ 158	$ (640)	$ 879	$ 1,007
Basic income (loss) per share of common stock:
From continuing operations	$ 0.01	$ (0.12)	$ 0.04	$ 0.28
From discontinued operations	(0.00)	(0.02)	(0.01)	(0.05)
Net income (loss) per basic share of common stock	0.01	(0.14)	0.04	0.23
Diluted income (loss) per share of common stock:
From continuing operations	0.01	(0.12)	0.04	0.04
From discontinued operations	(0.00)	(0.02)	(0.01)	(0.01)
Net income (loss) per diluted share of common stock	$ 0.01	$ (0.14)	$ 0.03	$ 0.04
Weighted average number of common shares and common share equivalents outstanding:
Basic	27,701	4,423	24,792	4,422
Diluted	27,713	4,423	27,245	27,697

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash Flows From Operating Activities
Net income	$ 879,000	$ 1,007,000
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	245,000	196,000
Amortization of deferred financing fees		26,000
Stock-based compensation	8,000	24,000
Deferred taxes	339,000
Asset impairment - lab supplies		198,000
Lab supplies write-off	217,000
Change in fair value of note payable		(18,000)
Amortization on operating lease right of use asset	216,000	193,000
Other changes in operating assets and liabilities:
Accounts receivable	(662,000)	1,313,000
Other current assets	(440,000)	(227,000)
Accounts payable	327,000	(409,000)
Accrued salaries and bonus	(934,000)	(176,000)
Other accrued expenses	231,000	(401,000)
Operating lease liabilities	(263,000)	(185,000)
Other long-term liabilities	218,000	214,000
Net cash provided by operating activities	381,000	1,755,000
Cash Flows From Investing Activity
Purchase of property and equipment	(198,000)	(201,000)
Net cash used in investing activities	(198,000)	(201,000)
Cash Flows From Financing Activities
Payments made on note payable		(2,500,000)
Series C conversion costs		(13,000)
Net cash used in financing activities		(2,513,000)
Net increase (decrease) in cash and cash equivalents	183,000	(959,000)
Cash and cash equivalents – beginning	2,505,000	1,461,000
Cash and cash equivalents – ending	$ 2,688,000	$ 502,000

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 2,688	$ 2,505
Accounts receivable	6,311	5,649
Other current assets	1,969	1,746
Total current assets	10,968	9,900
Property and equipment, net	1,621	1,423
Operating lease right of use assets	1,001	1,217
Deferred tax asset	20,915	21,254
Other long-term assets	44	44
Total assets	34,549	33,838
Current liabilities:
Accounts payable	1,555	983
Accrued salary and bonus	952	1,886
Other accrued expenses	1,784	1,574
Current liabilities of discontinued operations	660	660
Total current liabilities	4,951	5,103
Operating lease liabilities, net of current portion	516	752
Other long-term liabilities	5,838	5,620
Total liabilities	11,305	11,475
Commitments and contingencies (Note 7)
Stockholders’ equity:
Redeemable preferred stock, $.01 par value; 5,000,000 shares authorized, 0 and 47,000 shares Series C issued and outstanding, respectively
Common stock, $.01 par value; 100,000,000 shares authorized; 27,844,994 and 4,569,333 shares issued, respectively; 27,700,904 and 4,428,539 shares outstanding, respectively	640	407
Additional paid-in capital	234,608	234,833
Accumulated deficit	(209,926)	(210,805)
Treasury stock, at cost (144,090 and 140,794 shares, respectively)	(2,078)	(2,072)
Total stockholders’ equity	23,244	22,363
Total liabilities and stockholders’ equity	$ 34,549	$ 33,838